6Feuerstein G,Yue Th,Ma X,et al.Novel mechanisms in the treatment of heart failure:inbabition of oxygen redicals and apoptosis by Carvedilo[J].Prog Cardiovasc Dis,1998,41(1 suppli):17-24.
7Kantor PF.The antianginatl drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase[J].Cric Res,2000,86:580-588.
8Guarnieri C,Museasi C.Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardial muscle[J].Cardiovascular Ther,1996,814-815.
二级参考文献6
1Boddeke E,Hugtenburg J, Jap W, et al. New anti-ischaemic drugs;cytoprotective action with no primary haemodynamic effects. Trends Pharm Sci,1989,10(6) :397-400
2Lavancy N, Martin J, Rossi A. Anti-isohaemic effects of trimetazidine. 31 P-NMR spectroscopy in the isolated rat heart. Arch Intern Pharmacodyn Ther, 1987,286( 1 ) :97-110
3Detry JM,Sellier P, Pennaforte S,et al. Trimetazidine: a new concept in the treatment of angina:comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol, 1994,37 (4) :279-288
4Detry JM, Leclercq PJ. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol, 1995,76(1) :8B-11B
5Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina:a double-blind, crossover study. Cardiovasc Drugs Ther, 1990,4 ( Suppl 4 ): 853-859
6Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
